Stifel Financial Corp Sells 12,202 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Stifel Financial Corp decreased its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 15.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,759 shares of the medical research company's stock after selling 12,202 shares during the quarter. Stifel Financial Corp's holdings in Exact Sciences were worth $3,864,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Asset Planning Inc acquired a new position in shares of Exact Sciences in the fourth quarter worth about $40,000. Modus Advisors LLC acquired a new stake in shares of Exact Sciences in the 4th quarter worth approximately $43,000. AlphaQuest LLC grew its holdings in Exact Sciences by 22,825.0% during the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after acquiring an additional 913 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Exact Sciences during the 4th quarter valued at $66,000. Finally, Ostrum Asset Management boosted its holdings in shares of Exact Sciences by 28.4% in the fourth quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock worth $134,000 after buying an additional 527 shares during the period. Institutional investors and hedge funds own 88.82% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on EXAS shares. Robert W. Baird increased their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research report on Friday. Piper Sandler cut their target price on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Royal Bank of Canada upped their price objective on shares of Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a research note on Friday. Barclays upped their price objective on Exact Sciences from $55.00 to $75.00 and gave the stock an "overweight" rating in a report on Friday. Finally, Bank of America cut their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Two analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $70.90.

Exact Sciences Stock Performance

EXAS traded up $4.39 on Friday, reaching $51.55. The company had a trading volume of 6,908,837 shares, compared to its average volume of 2,637,409. The stock has a market cap of $9.72 billion, a P/E ratio of -9.25 and a beta of 0.92. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences Co. has a fifty-two week low of $39.97 and a fifty-two week high of $72.83. The company's fifty day moving average is $45.02 and its 200 day moving average is $53.20.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.16. The firm had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company's revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.60) EPS. As a group, analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.